Now that the market has opened for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, the next question is reimbursement. Will payers balk at an annual price tag upward of $14,000 for the new cholesterol-lowering biologics when statins are available for as little as a few dollars a month?